NASHVILLE, Tenn. / May 15, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:
B. Riley Securities 24th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, CA)
Format: Fireside Chat (In-Person), followed by 1x1 Investor Meetings
Date/Time: Wednesday, May 22, 2024, through Thursday, May 23, 2024
Craig-Hallum 21st Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN)
Format: 1x1 and Small Group Investor Meetings
Date/Time: Wednesday, May 29, 2024
Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum representative to request a meeting. Neither event will be webcast.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
Last Trade: | US$21.64 |
Daily Change: | 0.16 0.74 |
Daily Volume: | 346,862 |
Market Cap: | US$765.620M |
June 20, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB